Tandem Financial LLC bought a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,242 shares of the conglomerate's stock, valued at approximately $7,375,000. Danaher comprises about 2.2% of Tandem Financial LLC's portfolio, making the stock its 11th biggest holding.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Main Street Group LTD purchased a new position in shares of Danaher during the 1st quarter worth $25,000. N.E.W. Advisory Services LLC purchased a new stake in Danaher in the 2nd quarter valued at about $25,000. JPL Wealth Management LLC purchased a new stake in Danaher in the 3rd quarter valued at about $25,000. WFA of San Diego LLC acquired a new position in Danaher in the second quarter valued at about $26,000. Finally, Hilton Head Capital Partners LLC purchased a new position in Danaher during the fourth quarter worth about $27,000. Hedge funds and other institutional investors own 79.05% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on DHR shares. TD Cowen dropped their price target on shares of Danaher from $240.00 to $236.00 and set a "buy" rating for the company in a research report on Wednesday, July 22nd. Guggenheim decreased their price objective on shares of Danaher from $235.00 to $200.00 and set a "buy" rating on the stock in a report on Wednesday, July 22nd. Stifel Nicolaus lowered their price objective on shares of Danaher from $260.00 to $220.00 and set a "buy" rating for the company in a research report on Wednesday, July 22nd. HSBC dropped their target price on shares of Danaher from $270.00 to $230.00 and set a "buy" rating for the company in a report on Wednesday, June 3rd. Finally, Piper Sandler initiated coverage on Danaher in a research report on Thursday, June 11th. They issued a "neutral" rating and a $200.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $228.91.
View Our Latest Analysis on DHR
Danaher Trading Down 1.7%
Shares of NYSE:DHR opened at $215.18 on Tuesday. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company's 50 day moving average is $196.49 and its two-hundred day moving average is $192.39. The company has a market cap of $151.27 billion, a PE ratio of 38.22, a P/E/G ratio of 2.72 and a beta of 0.78. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.
Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts' expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company's revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.77 EPS. Equities analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.
Danaher Company Profile
(
Free Report)
Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.